Replies to post #12813 on Todos Med Ltd (TOMDF)

[delerious1]

Good discussion today for TOMDF .....but Newco after newco..."go big or go bust"...don't worry about TOMDF or what's left of it ....."shareholders will be fine"...
"if you don't like it leave. ",,,,"investor"

GM you stated "They (TODOS) will get 52% of 3CL revenues."....from Gross revenue or net revenue?

Another stated:" Todos will sell some of their 52% to investors. Give away some to new management team. And retain an unknown amount. If I had to guess I would say 25%. " When you say Todos you say TOMDF so we pay for development then our cut goes down to perhaps 25% or less. And this is good?

Discussion should be about what's in it for us, as shareholders and do we even have a say anymore. Why sell off our assets, what about fiduciary duty to shareholders.?

[GreeseMonkey]

Todos isn't selling part of their 52%. 3CL Pharma was independently assessed and valued at $1.9B. They won't be trying to raise that much. They wouldn't want to sell that many shares, but only sell enough to fund their initiatives and operating costs until revenues are sufficient to cover all of this.

It has not been determined yet if shareholders will get individual shares in the spinoff. One could assume if that's the case, that part may come out of Todos 52% ownership portion. It makes sense the final ratio of ownership will be spread among Todos, 3CL Pharma, and outside investors participating in the capital raise, so that the combined ownership of all 3 equals 100% of the existing share structure at the spinoff. Todos percentage should drop, but they should still have the majority ownership position.

The key point in my mind is that Todos has the option to acquire 100% of the new entity and has the share structure in place to make that happen, but this only makes sense after the uplist to NYSE.